Evaluation of sarcopenia and sarcopenic obesity in patients affected by oral squamous cell carcinoma: A retrospective single-center study.

This retrospective single-center study aimed to evaluate the relevance of sarcopenia and sarcopenic obesity as negative prognostic factors in patients with oral squamous cell carcinoma (OSCC). The study was performed on patients who underwent oral squamous cell carcinoma resection surgery. Patients' demographic and clinical variables were collected at diagnosis (sex, age, height, weight, comorbidities, smoke and alcohol consumption, HPV positivity, TNM-stage) and corrected for known prognostic factors (age, body mass index, TNM-stage). The Skeletal Muscle Mass (SMM) and the Cross-Sectional Area (CSA) on pre-treatment CT scans and Body Mass Index (BMI) were measured to assess sarcopenia and sarcopenic obesity correlated to overall survival (OS). Chi-square statistics were used to analyze the differences between the frequencies of each categorical variable with the presence or absence of sarcopenia and sarcopenic obesity. The cumulative overall survival was calculated by the Kaplan-Meier method, and the differences between curves were evaluated by the log-rank test. A Cox proportional hazard regression model was used for univariate and multivariate analysis of the overall survival. Within the limitations of the study, in this sample, sarcopenia did not seem to cause a statistically significant reduction in the overall survival in patients with oral squamous cell carcinoma (Log Rank χ2 = 3.67, p = 0.055; HR 0.996, 95% CI 0.732-1.354, p = 0.979), however, sarcopenic obesity showed a meaningful negative prognostic impact on it (Log Rank χ2 = 5.71, p = 0.017; HR 0.985, 95% CI 0.424-2.286, p = 0.972). Within the limitations of the study it seems that sarcopenic obesity, age, BMI, and TNM-stage are more relevant negative prognostic factors, influencing overall survival in surgically treated OSCC, than sarcopenia.

A new surgical approach for the treatment of Rhinophyma.

BACKGROUND: Rhinophyma is a rare and benign pathological condition affecting the nose. It can be localized or generalized causing a nasal deformity, mainly of the lower 2/3 of the nose. Clinically, rhinophyma is characterized by the aberrant development of the vascularization of the skin of the nose. The nose becomes particularly sensitive, and even a minimal external trauma can cause bleeding. Different treatment methods have been described during the last few years, but surgery still remains the gold standard. The aim is to obtain a reduction of the abnormal tissue, by debulking and fine contouring followed by hemostasis and a very careful postoperative care. Herein we report one case of Rhinophyma treated with the Microdebrider (Storz®). CASE REPORT: A 70 year old male with a diagnosis of rhinophyma was admitted to the Department of Maxillo-Facial Surgery of "Federico II" University of Naples. The patient underwent a debridment of rhinophyma, combining dermabrasion and decortication, using a Microdebrider (Storz®). After the surgery, the wound was covered with an advanced dressing, a collagen sponge equina (Condress®) applied at the end of the procedure and routinely during the follow up control to promote the healing process. CONCLUSION: After 2 months the patient was completely healed without any complications and without any signs of recurrence, obtaining a good aesthetic and functional result. After 25 months of follow up the result is still stable. KEY WORDS: Rhinophyma, Microdebrider.